Peer-influenced content. Sources you trust. No registration required. This is HCN.

MedPage TodayBispecific Antibody Shows Promise in R/R Multiple Myeloma

Publication: The Lancet
Open-label, single-arm study of 157 patients who had undergone a median of six previous lines of therapy and who received at least one dose of teclistamab; 40 patients received the recommended phase II dose of teclistamab
Of the 40 receiving the phase II dose, 58% achieved a very good partial response or better; 40% achieved a complete response or better

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form